| 0 (0%) | 09-27 09:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.54 | 1-year : | 22.83 |
| Resists | First : | 16.73 | Second : | 19.54 |
| Pivot price | 16 |
|||
| Supports | First : | 14.79 | Second : | 13.6 |
| MAs | MA(5) : | 16.38 |
MA(20) : | 15.6 |
| MA(100) : | 13.4 |
MA(250) : | 13.43 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 85.2 |
D(3) : | 85.6  |
| RSI | RSI(14): 65.5 |
|||
| 52-week | High : | 17.7 | Low : | 9.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ZYME ] has closed below upper band by 18.1%. Bollinger Bands are 15.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.67 - 16.77 | 16.77 - 16.86 |
| Low: | 15.83 - 15.94 | 15.94 - 16.05 |
| Close: | 16.42 - 16.59 | 16.59 - 16.76 |
Tue, 23 Sep 2025
Zymeworks Inc. $ZYME Shares Sold by Rhumbline Advisers - MarketBeat
Mon, 22 Sep 2025
Zymeworks drops as Wells Fargo cuts on valuation - MSN
Sat, 20 Sep 2025
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Zymeworks (ZYME) - The Globe and Mail
Fri, 19 Sep 2025
Zymeworks Inc. $ZYME Stock Holdings Lifted by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC - MarketBeat
Sat, 13 Sep 2025
How Investors May Respond To Zymeworks (ZYME) Ending ZW171 Trials and Focusing on Zanidatamab - simplywall.st
Thu, 11 Sep 2025
Zymeworks (ZYME): Evaluating Valuation After Global Approvals for Zanidatamab and Pipeline Progress - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 75 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 101.4 (%) |
| Shares Short | 6,890 (K) |
| Shares Short P.Month | 6,810 (K) |
| EPS | -0.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.46 |
| Profit Margin | -60 % |
| Operating Margin | -1.4 % |
| Return on Assets (ttm) | -11.2 % |
| Return on Equity (ttm) | -19.9 % |
| Qtrly Rev. Growth | 153.1 % |
| Gross Profit (p.s.) | -0.28 |
| Sales Per Share | 1.63 |
| EBITDA (p.s.) | -0.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -16.94 |
| PEG Ratio | 0 |
| Price to Book value | 3.71 |
| Price to Sales | 10.15 |
| Price to Cash Flow | -32.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|